ProMIS Neurosciences

ProMIS Neurosciences FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of ProMIS Neurosciences (PMN.TO) as of Oct 15, 2026 is 94.32 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 95.11 % — a change of -0.83% (lower).

FCF Conversion

94.32 %

YoY

-0.83%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of ProMIS Neurosciences is 2022 94.32 % . FCF Conversion Rate (FCF/EBITDA) of ProMIS Neurosciences was 2021 95.11 % . It decreases by -0.83% lower compared to the previous year.

The ProMIS Neurosciences FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
74.06 CAD
Jan 1, 2016
73.62 CAD
Jan 1, 2017
94.68 CAD
Jan 1, 2018
84.96 CAD
Jan 1, 2019
82.30 CAD
Jan 1, 2020
78.80 CAD
Jan 1, 2021
95.11 CAD
Jan 1, 2022
94.32 CAD
The ProMIS Neurosciences FCF Conversion history
YEARFCF ConversionYoY
94.32 %-0.83%
95.11 %+20.70%
78.80 %-4.25%
82.30 %-3.13%
84.96 %-10.27%
94.68 %+28.61%
73.62 %-0.59%
74.06 %+15.68%
64.02 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProMIS Neurosciences Stock analysis

What does ProMIS Neurosciences do? ProMIS Neurosciences Inc is a biopharmaceutical company based in Canada that specializes in the discovery and development of novel therapeutics for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company was founded in 2004 and has been listed on the Toronto Stock Exchange since 2015. The goal of ProMIS is to develop highly specific therapeutics that specifically target the cellular causes of neurodegenerative diseases and can therefore stop or even reverse the progression of the disease. The company utilizes its proprietary platform technology to identify the unique epitopes on the pathological proteins that are specific to neurodegenerative diseases. ProMIS' business model is based on partnerships with large pharmaceutical companies that are searching for new therapeutics for neurodegenerative diseases. ProMIS works closely with these partners to develop customized therapeutics tailored to each partner's specific needs. The company licenses its technology and products to its partners and receives license and milestone payments when certain development or sales goals are achieved. ProMIS has different divisions to focus on various neurodegenerative diseases, with a focus on Alzheimer's, Parkinson's, and ALS. ProMIS has a comprehensive research and development infrastructure that focuses on the identification, characterization, and optimization of therapeutic antibodies and biomarkers. In terms of products, ProMIS has developed various antibodies that specifically target pathological proteins such as Aß and Tau in Alzheimer's and alpha-synuclein in Parkinson's. These antibodies can selectively recognize and bind to these pathological proteins, allowing them to be broken down and removed from the body. ProMIS works closely with its partners to test these antibodies in clinical trials and eventually bring them to market. In addition to its antibody products, ProMIS has also developed neuromethods that allow researchers to characterize and quantify the functions of proteins in brain cells and in vivo. These methods can be used to test and optimize the effects of antibodies and other therapeutics, making them an important part of ProMIS' development infrastructure. Overall, ProMIS Neurosciences Inc is an innovative biopharmaceutical company that focuses on the development of highly specific therapeutics for neurodegenerative diseases. The company has a comprehensive infrastructure and technology platform that allows it to develop customized products for its partners. With its antibodies and neuromethods, ProMIS has the potential to make a breakthrough in the treatment of neurodegenerative diseases and improve the lives of millions of patients. ProMIS Neurosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProMIS Neurosciences stock

FCF Conversion Rate (FCF/EBITDA) of ProMIS Neurosciences is 94.32 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of ProMIS Neurosciences changed from 95.11 % to 94.32 %, representing a -0.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) ProMIS Neurosciences since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s ProMIS Neurosciences with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ProMIS Neurosciences

All Key Metrics — ProMIS Neurosciences